A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...